Please ensure Javascript is enabled for purposes of website accessibility

Here's What You Need to Know From Amarin's Q1 Earnings Update

By Keith Speights - May 1, 2019 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biotech continued to enjoy strong sales for Vascepa. But even better news could be on the way.

Amarin Corporation plc (AMRN -3.65%) could be sitting on a goldmine with its cardiovascular drug Vascepa. But how much gold did the drugmaker actually mine in the first quarter? Investors just got an answer to that question.

The company announced its first-quarter results before the market opened on Wednesday. Here's what you need to know from Amarin's quarterly update.

Physician holding up a pill

Image source: Getty Images.

By the numbers

Amarin announced Q1 revenue of $73.3 million, a 67% increase from the $43.9 million reported in the same quarter of the previous year. The company's reported revenue easily beat the average analysts' revenue estimate of $67.3 million. 

The company announced a GAAP net loss of $24.4 million, or $0.07 per share, in the first quarter. This represented a small deterioration from the loss of $24.1 million, or $0.08 per share, reported in the same quarter of 2018.

How did Amarin's adjusted non-GAAP bottom line look in the first quarter? The company reported an adjusted net loss of $17.5 million, or $0.05 per share, compared to $20.3 million, or $0.07 per share, in the same period in 2018. This beat the average analysts' earnings estimate of a loss of $0.11 per share.

Behind the numbers

The primary driver of Amarin's first-quarter revenue growth was higher prescription volume for Vascepa. Amarin said that prescription growth of the triglyceride-lowering drug rose by 58% in Q1 based on data from Symphony Health, and by 55% based on data from IQVIA.

This growth is especially impressive considering that the first quarter is typically lower due to seasonal factors, notably including the fact that patients' deductibles reset at the beginning of the year. Despite these factors, Vascepa still generated strong sales growth thanks in large part to a big jump in new prescriptions. 

Amarin's bottom line was a little worse than it was in the prior-year period. However, that's understandable, considering that the company spent more on promotional activities for Vascepa. It helped, though, that research and development expenses declined as a result of lowered costs following the completion of the Reduce-It study.

Other key achievements from Amarin's first quarter included:

  • Priority review granted for Vascepa in Canada.
  • Filed for FDA approval of an expanded indication for Vascepa in March based on the positive clinical results from the Reduce-It cardiovascular outcomes study that ended in late 2018.
  • The American Diabetes Association (ADA) incorporated Reduce-It results to update its 2019 Standards of Medical Care in Diabetes.

Looking ahead

There are several things that investors can look forward to in the near future. The most important of these is the anticipated FDA approval of the supplemental New Drug Application (sNDA) for Vascepa based on the Reduce-It cardiovascular outcomes study results. This decision could be handed down by January 2020.

In the meantime, Amarin's investments in beefing up its sales force could begin to pay off. The company more than doubled the size of its U.S. sales team and now has around 400 sales reps in the field. These new reps were trained and deployed by the middle of January. Amarin could see increased sales for Vascepa over the next few quarters as its larger sales team reaches out to healthcare professionals.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.85 (-3.65%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.